Press Release | Sirnaomics
Summary
Sirnaomics intends to build on the recent success demonstrated by other companies in the sector by leveraging our tremendous knowledge and experience in RNAi and delivery technologies. We are very excited to bring our lead product candidate, STP705, to the clinic this year for the treatment of Hypertrophic Scar, said the Founder and CEO of the company, Dr. Patrick Y. Lu. We expect to file IND to US FDA in early third quarter of 2016 and to initiate the phase 1 clinical study soon after the filing.The PNP (polypeptide Nanoparticle) siRNA formulation of our leading drug candidate, STP705, had been extensively validated and shown to be very versatile with a simple straight forward manufacturing process, said Dr. Marc Lemaitre, Sirnaomics Chief Operation Officer. Although their causative mechanisms are quite diverse, these diseases share the common feature of prolong inflammation and uncontrolled accumulation of fibrous tissue macromolecules in affected organs leading to their dysfunction and ultimate failure.Sirnaomics STP705 is an anti-fibrosis siRNA (small interfering RNA) therapeutic candidate, taking advantage of a dual-targeted inhibitory property and PNP-enhanced delivery to directly diminish the tissue fibrotic activity in various animal models, from skin hypertrophic scar to liver and lung fibrosis. A fully-developed manufacturing process and a well-established pre-clinical safety profile ensure STP705 for human clinical studies with a broad application potential.Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China.